Prime Medicine, Inc. announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The company expects to raise approximately $125.4 million in gross proceeds from this offering, before deducting underwriting discounts, commissions, and offering expenses. This capital raise is intended to support the company's ongoing operations and pipeline development.
The underwriters were granted a 30-day option to purchase up to an additional 5,700,000 shares of common stock. Notably, 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation in this offering will not incur any underwriting discounts or commissions. All shares in the offering are being sold by Prime Medicine itself.
The offering is expected to close on or about August 1, 2025, subject to customary closing conditions. This financing move is a critical step for Prime Medicine to secure capital, enabling it to continue advancing its gene editing therapies, particularly its prioritized liver franchise programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.